Discovery of a potent dual ALK and EGFR T790M inhibitor.

about

Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

P2860

Q48231295-4CCFD492-694B-4771-A241-52848BF5329D

P2860

Discovery of a potent dual ALK and EGFR T790M inhibitor.

Item

http://www.wikidata.org/entity/Q38702793

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Discovery of a potent dual ALK and EGFR T790M inhibitor.

@en

type

Item

label

Discovery of a potent dual ALK and EGFR T790M inhibitor.

@en

prefLabel

Discovery of a potent dual ALK and EGFR T790M inhibitor.

@en

P1476

Discovery of a potent dual ALK and EGFR T790M inhibitor.

@en

P2093

Ciric To

http://www.w3.org/2001/XMLSchema#string

Hwan Geun Choi

http://www.w3.org/2001/XMLSchema#string

Jaebong Jang

http://www.w3.org/2001/XMLSchema#string

Jung Beom Son

http://www.w3.org/2001/XMLSchema#string

Magda Bahcall

http://www.w3.org/2001/XMLSchema#string

Mierzhati Mushajiang

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Seock Yong Kang

http://www.w3.org/2001/XMLSchema#string

So Young Kim

http://www.w3.org/2001/XMLSchema#string

Younho Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Cell signaling by receptor tyrosine kinases

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Targeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen Bond

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

P304

497-510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJMECH.2017.04.079

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Pasi A Jänne

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28528303

http://www.w3.org/2001/XMLSchema#string

P932

5800871

http://www.w3.org/2001/XMLSchema#string

Discovery of a potent dual ALK and EGFR T790M inhibitor.

about

P2860

P2860

Discovery of a potent dual ALK and EGFR T790M inhibitor.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932